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Abstract (150 words) 
 
The International Transporter Consortium (ITC) has described recently seven transporters of 
particular relevance for drug development (Giacomini et al., Nat. Rev. Drug Discov. 9: 215-236, 
2010). Based on the second ITC transporter workshop in 2012, we have identified additional 
transporters of emerging importance in pharmacokinetics, interference of drugs with transport of 
endogenous compounds and drug-drug interactions in humans. The multidrug and toxin 
extrusion proteins (MATEs, gene symbol SLC47A) mediate excretion of organic cations into bile 
and urine. MATEs are important in renal drug-drug interactions. Multidrug resistance proteins 
(MRPs or ABCCs) are drug and conjugate efflux pumps, and impaired activity of MRP2 results 
in conjugated hyperbilirubinemia. The bile salt export pump (BSEP or ABCB11) prevents 
accumulation of toxic bile salt concentrations in hepatocytes, and BSEP inhibition or deficiency 
may cause cholestasis and liver injury. Additionally, examples are presented on the roles of 
nucleoside and peptide transporters in drug targeting and disposition. 
 
 
INTRODUCTION  
 
 Transporters are membrane bound proteins that control access of endogenous substances 
and xenobiotics (drugs) to various sites of the human body (1, 2).  In contrast to drug 
metabolizing enzymes, which are largely concentrated in the liver and intestine, transporters are 
present in all tissues in the body and play important roles in drug absorption, distribution, tissue-
specific drug targeting, and elimination, thus influencing drug pharmacokinetics (PK) and 
pharmacodynamics (PD). Transporters can also work in concert with metabolizing enzymes in 
affecting a drug’s PK and PD.  Similar to metabolizing enzymes, transporters have substrate 
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binding sites that are saturable and can be inhibited (3).  Moreover, some transporters are 
inducible, or can change their localization by endocytic retrieval and exocytic insertion (3). 
 
 The human genome project has identified more than 400 transporters that belong to one 
of two superfamilies:  ATP-binding Cassette (ABC) or Solute Carrier (SLC).   Changes in 
transporter expression or activity either via genetic factors or drug-drug interactions (DDIs) can 
contribute to variability in drug exposure and response.  The advancement of molecular cloning 
of cDNAs encoding various transporters and in vitro cell expression systems to study 
interactions of drugs with transporters has enabled researchers to examine the underlying 
mechanisms of DDIs mediated by transporters.  This improved understanding has provided the 
foundation to predict in vivo DDIs based on in vitro assays.  For example, it was found that many 
statin drugs are substrates of the organic anion transporting polypeptide (OATP1B1, gene 
symbol SLCO1B1); their interactions with cyclosporine (a broad transporter and enzyme 
inhibitor) are therefore “anticipated”.  In addition, recent findings that many HIV protease 
inhibitors are OATP1B1/OATP1B3 inhibitors are critical in the design of  clinical DDI studies to 
manage a myriad of potential drug interactions between HIV protease inhibitors and other 
concomitantly administered drugs, including statins (4).    
 
 In 2007, the International Transporter Consortium (ITC), which includes members from 
academia, industry and the Food and Drug Administration (FDA), was formed with the goal of 
determining transporters that are of emerging importance in clinical DDIs, establishing standards 
for in vitro evaluation of transporter-based interactions that may reduce the need for in vivo 
studies, and achieving, where possible, a consensus on current knowledge of transporters in drug 
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development (5). The ITC organized an FDA critical path initiative-funded transporter workshop 
in October 2008 and authored a transporter whitepaper that was published in Nature Reviews 
Drug Discovery in March of 2010 (2).  The publication shared experiences, stimulated further 
discussion, and provided strategic directions in the following scientific areas: key transporters 
with clinical implications, in vitro methodologies, and decision trees for key transporters as to 
when to conduct in vitro and in vivo DDI evaluations (2).  
 
 The ITC whitepaper identified seven transporters as having compelling clinical evidence 
of involvement in clinical DDIs (Figure 1).  These were: P-gp (MDR1, gene symbol ABCB1), 
breast cancer resistance protein (BCRP, ABCG2), OATP1B1, OATP1B3 (gene symbols 
SLCO1B1 and SLCO1B3), organic cation transporter 2 (OCT2, SLC22A2) and organic anion 
transporters 1 and 3 (OAT1/OAT3, SLC22A6/SLC22A7) (2).   The whitepaper recommended that 
these transporters should be studied in vitro to determine the potential of clinical DDIs and 
proposed decision trees to determine if clinical studies should be conducted to evaluate the 
propensity for clinically relevant DDIs. 
 
 The FDA’s 2012 draft drug interaction guidance (6) included recommendations on when 
to evaluate transporter-based DDIs.   The European Medicines Agency (EMA) also included 
recommendations on transporters in their recently published drug interaction guidelines (7).  
 
 In addition to contributing to DDIs, transporters may contribute to drug tissue toxicity or 
serve as treatment targets.  In March 2012, the ITC organized a second transporter workshop that 
included discussions of emerging transporters involved in DDIs, efficacy, and drug induced 
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toxicity, including multidrug and toxin extrusion transporters (MATEs, gene symbol SLC47A), 
multidrug resistance proteins (MRPs, ABCCs, gene symbols ABCCs) and the bile salt export 
pump (BSEP, ABCB11, gene symbol  ABCB11) (Figure 1) (8).  In addition, clinically important 
examples involving nucleoside transporters and peptide transporters were also presented (8). 
 
 The goal of this whitepaper is to discuss the research and clinical observations available 
for emerging transporters of clinical importance.  The clinical relevance and importance of these 
transporters and recommendations on how to study them during drug development and what 
criteria may be used to assess their role in DDIs and toxicity are discussed.  
 
The emerging transporters MATE1 and MATE2K 
 
General description 
 The multidrug and toxin extrusion proteins (MATEs) include three major functional 
solute carriers: MATE1 (SLC47A1), MATE2 (SLC47A2) and the splice variant MATE2K. The 
three functional isoforms are expressed abundantly in the apical membrane of the renal proximal 
tubule and play roles in the secretion of cations and zwitterions into urine (1, 9, 10). They 
function as cation/H+ antiporters in tandem with organic cation transporters (e.g., OCT2) 
localized at the basolateral membrane of proximal tubule cells. In addition, MATE1 is highly 
expressed on the canalicular membrane of hepatocytes where it appears to cooperate with OCT1 
in mediating biliary excretion. The PK, efficacy, safety and/or tissue levels of a substrate of 
MATEs may be altered by changes in transporter function and/or level of expression caused by 
genetic polymorphisms or DDIs. For more detail, see recent reviews that describe molecular 
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characteristics, expression and function of MATEs (9, 10). Current evidence is strongest for 
MATE1 and MATE2K and accordingly this consortium update focuses on them.   
 
Structure 
 The human SLC47A1 (MATE1) and SLC47A2 (MATE2) genes are located in tandem on 
chromosome 17p11.2 and encode membrane proteins of 570 and 602 amino acids, respectively 
(11). MATE2K, which lacks part of exon 7 due to alternative splicing, is a 566 amino acid 
protein.  Various structural studies suggest that human MATE1 topology includes a 13 
transmembrane helix with an extracellular COOH terminus (12). Homology models of human 
MATEs based on the available bacterial X-ray structure (i.e., NorM) are emerging but have not 
yet been used effectively in structure based screens of large drug databases (13). Site directed 
mutagenesis studies of human MATEs have identified several structural motifs with importance 
for transport activity (a detailed list of residues can be found in the supplementary material).  
 
Genetic variants 
 Polymorphisms found in the SLC47A1 and SLC47A2 genes include both regulatory 
single nucleotide polymorphisms (rSNPs) and non-synonymous and synonymous SNPs in the 
coding region (cSNPs) (9).  Seven rSNPs in MATE1/2 have been characterized in reporter 
assays, and fifteen cSNPs have been characterized in transporter assays (14). A detailed list of 
the reported polymorphisms in the two genes is summarized in Supplementary Table 1.  The 
clinical significance of some of these SNPs has been linked to clinical effects in metformin 
treated subjects.  Separate studies have shown that the MATE1 intronic variants rs2289669 and 
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rs8065082 have significant effects on metformin response. Similarly a common promoter region 
variant in MATE2K, rs12943590 (-130G>A), was associated with reduced metformin response 
(15).  
 
Methodology for evaluating function 
 Under physiological conditions, proximal tubule cells express MATE1 and MATE2K in 
the brush border membrane, where sodium/proton exchangers maintain a proton gradient in 
which the extracellular fluids of the tubule lumen are slightly more acidic than the cytosol. For in 
vitro studies, cell lines expressing MATE1 and MATE2 or MATE2K are recommended. 
Currently, there is little information on differences in substrate or inhibitor specificity between 
MATE2 and MATE2K, therefore, cell lines expressing MATE2K are generally used as models 
of both MATE2 isoforms. Several in vitro assays have been designed to mimic physiologic 
parameters with epithelial cell lines and used to test MATE1 or MATE2K function. Human 
Embryonic Kidney cells (HEK), Chinese Hamster Ovary cells (CHO) or Madin-Darby Canine 
Kidney cells (MDCK) are the most commonly used cell lines and are transfected with a MATE 
recombinant ortholog or vector control and used in adherent culture. Ammonia pre-pulse is 
commonly used to acidify the cytosol and reverse transport direction. Then a substrate is applied 
and taken into the cell against the flux of protons from the cytosol. Although these assays 
measure substrate influx, MATEs exhibit reversible transport, and the assays can be easily used 
to identify MATE ligands. Variations to the experimental setting have been reported and include 
extracellular pH changes to avoid preloading of cells, and use of polarized cells and double 
transfected cells (MATE1/2K and OCT2) for measurement of transport through a monolayer of 
differentiated cells (16). These in vitro assays are instrumental when assessing whether a new 
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molecular entity (NME) is a MATE substrate or inhibitor (17). Mouse is the preferred animal 
model to study Mate1, but not Mate2 because mice do not express either Mate2 or Mate2K in 
their kidneys (18).  Mice have two functional genomic variants for Slc47a1 (i.e., mSlc471a and 
mSlc471b).(9, 10). mMate1 knockout mice have been instrumental in elucidating the systemic 
distribution and clearance of endogenous compounds and xenobiotics in vivo. The physiologic 
and pharmacological relevance of mMate1 has been demonstrated for metformin, cephalexin, 
cisplatin, paraquat and other molecules, and usually correlates well with the human ortholog. 
However, differences in ligand affinity between orthologs as well as general limitations of 
interpretation of rodent PK data (e.g., Cyp450 activity) need to be considered (Supplementary 
Table 2).      
 
Substrate and inhibitor selectivity 
 To date, over 900 compounds have been tested as substrates and inhibitors of MATEs, 
and several structure activity relationship models have been proposed.  Typical substrates for 
MATEs, which overlap with OCT substrates, are hydrophilic, low molecular weight organic 
cations such as metformin and 1-methyl-4-phenylpyridinium (MPP+).  However, in contrast to 
OCTs, MATEs appear to transport a wider range of chemical structures including anionic 
compounds (e.g., acyclovir, gancyclovir and estrone sulfate) and zwitterions (e.g., cephalexine 
and cephradine). Supplementary Table 2 lists various ligands reported in the literature and their 
relative selectivities for MATEs or OCTs. For transepithelial flux, it is thought that MATEs 
partner with OCTs for cationic substrates and with organic anion transporters (OATs) for 
zwitterionic and anionic substrates. The substrate specificities of MATE1 and MATE2K are 
highly similar, but not identical, as is underscored by the MATE2K preferred substrate, 
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oxaliplatin, which interacts poorly with MATE1. Physicochemical properties of inhibitors of 
MATE1 and MATE2K include a positive charge at pH 7.4, a high LogP value and a large 
molecular weight (16, 17).  Selectivity for MATEs over OCT2 is exhibited by cimetidine and 
pyrimethamine, both of which can interact with MATEs at clinically relevant concentrations.      
 
Clinical significance and drug development recommendations 
 Two lines of evidence suggest that MATEs are important determinants of both PK and 
PD in humans.  First, as noted above, studies of genetic polymorphisms in both SLC47A1 and 
SLC47A2 suggest that these transporters play important roles in the renal elimination and 
pharmacologic effects of metformin. In some cases measurement of PD endpoints seem more 
sensitive for DDI identification than apparent changes in plasma concentrations.  Second, DDI 
studies with selective inhibitors of MATEs such as cimetidine and pyrimethamine (e.g., >10–
fold more potent in comparison to OCT2) have demonstrated substantial effects of MATE 
inhibitors on renal drug clearance and drug concentrations in plasma (AUC and Cmax) (Table 1).   
Previous studies had suggested that cimetidine causes DDIs by inhibiting OCT2; however, in 
light of the in vitro studies showing that cimetidine interacts more potently with MATEs than 
with OCT2, these DDIs are now believed to be mediated through inhibition of MATE1 and/or 
MATE2K.  
 
In view of the strong in vitro and in vivo evidence that MATEs are sites of renal DDIs, 
the ITC recommends that clinical decision trees for evaluating the interactions of MATEs with 
NMEs be adopted and included along with OCT2 and OAT1/OAT3 (Figures 2 and 3). The 
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first decision tree, is targeted to NMEs for which renal secretion is an important route of 
drug elimination. For such compounds, in vitro uptake studies in MATE transfected cells are 
recommended. If the NME is found to be a substrate of MATEs (or OCT2), a clinical study is 
recommended to be considered with cimetidine or pyrimethamine as inhibitors. When evaluating 
the potential of a NME to cause a DDI due to inhibition of MATEs, the decision tree in Figure 3, 
which is based on previously published ITC recommended cutoffs, suggests an empirical 
approach (4). That is, therapeutic maximum unbound concentrations of the NME that are greater 
than or equal to 1/10th of its in vitro IC50 or Ki value suggest a DDI potential with drugs that are 
substrates for MATEs or OCT2.  For most clinical studies of MATE substrates or inhibitors, 
creatinine clearance, which is often used as a measure of filtration clearance, may be replaced by 
other methods to evaluate filtration clearance since creatinine is a substrate of MATEs (19, 20). 
 
 
Multidrug Resistance Proteins (MRPs, ABCCs): The drug and conjugate efflux pumps 
MRP2, MRP3, and MRP4  
General description 
 Among the nine multidrug resistance proteins (MRPs) encoded in the human genome, 
MRP2 (ABCC2), MRP3 (ABCC3), and MRP4 (ABCC4) have received particular attention 
because of their roles in the disposition of drugs and conjugates (21). MRPs are unidirectional, 
ATP-dependent efflux pumps in the plasma membrane of human cells and many other organisms 
(22). Human MRP2, formerly also termed canalicular multispecific organic anion transporter 
(cMOAT), was the second member of the MRP subfamily to be identified by molecular cloning 
of its cDNA, and is localized to the apical membrane of hepatocytes, intestinal epithelia, and 
proximal tubules of the kidney (23).  Accordingly, it is essential for hepatobiliary and renal 
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elimination of many anionic substrates, including drugs and conjugates such as bilirubin 
glucuronides. Conjugated hyperbilirubinemia in patients suggests MRP2 dysfunction. MRP2 of 
intestinal epithelia pumps its substrates into the intestinal lumen. In hepatocytes, MRP3 and 
MRP4 are localized to the basolateral (sinusoidal) membrane and mediate efflux of substrates, 
particularly glucuronides and glutathione conjugates, into sinusoidal blood. Thus, they play a 
compensatory role under conditions of cholestasis and when MRP2 function is impaired. MRP4 
has a number of additional localizations important for drug elimination and action: it is localized 
to the apical (luminal) membrane of kidney proximal tubules and epithelia of the blood-brain 
barrier (24)  and to membranes of blood platelets (25).  
 
Structure and function 
 Human MRP2 is an integral plasma membrane glycoprotein composed of 1,545 amino 
acids. The total number of amino acids for MRP3 and MRP4 is 1,527 and 1,325, respectively, 
and the amino acid identities of MRP2 compared to MRP3 and MRP4 are 48% and 39%, 
respectively (22, 23). All MRPs contain two ATP-binding domains. The ABCC genes encoding 
the MRP transport proteins considered here are located on different chromosomes, namely 10q24 
for MRP2, 17q22 for MRP3, and 13q32 for MRP4 (22, 23). At present, MRP2 orthologs have 
been cloned from more than 20 organisms, ranging from cellular slime molds, plants, bony fishes, 
and birds to many mammalian species, including human, rat, mouse, dog, rabbit, and monkey. 
Thus, MRP2 is a phylogenetically ancient efflux pump involved in detoxification. Genetic 
variants in mammals leading to an inactive MRP2 transporter are usually well compensated by 
alternative efflux pathways, including basolateral hepatocellular MRP3 and apical MRP4 in 
kidney proximal tubule cells. 
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 The members of the MRP subfamily exhibit an overlap in substrate selectivity, but differ 
in cell and tissue distribution and in domain-specific cellular localization (21). MRP2 is the only 
member that is localized exclusively to the apical membrane domain of polarized cells. Specific 
antibodies serve to localize the MRP2 protein in the apical domain of various polarized cell types, 
including hepatocytes, kidney proximal tubule cells, human small intestine, colon, gall bladder, 
segments of bronchi, and placenta. MRP2 protein is absent or below current detection limits in 
several other normal human cell types and tissues, including endothelial cells of the blood-brain 
barrier. 
 
 Typical substrates for which both human MRP2 and rat Mrp2 have high affinities include 
many glutathione conjugates of drugs and endogenous compounds, notably the arachidonic acid-
derived glutathione conjugate termed leukotriene C4 , as well as glucuronic acid conjugates, 
including bilirubin monoglucuronide and bilirubin bisglucuronide (23). Synthetic substrates 
include bromosulfophthalein, cholecystokinin octapeptide (CCK-8), cholyl-L-lysyl-fluorescein, 
fluo-3, carboxy-2’,7’-dichlorofluorescein (CDF), and methotrexate. Major differences in the 
substrate specificities of recombinant human and rat MRP2/Mrp2 have not yet been detected 
(23).  
 
 Important substrates for human MRP3 include glucuronic acid conjugates of drugs and 
endogenous substances (26), particularly bilirubin monoglucuronide and bilirubin bisglucuronide 
(21). MRP3 plays a clinically important role in jaundice with conjugated hyperbilirubinemia. It 
is the interaction between canalicular MRP2 and sinusoidal (basolateral) MRP3 with efflux of 
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bilirubin glucuronides from hepatocytes into blood that explains the conjugated 
hyperbilirubinemia in cholestasis and under conditions of impaired function of MRP2 . 
Subsequently, bilirubin glucuronides can be eliminated via the kidneys into urine. In intestinal 
epithelia, basolateral MRP3 may also function in transport of glucuronides, formed 
intracellularly, into blood. Detailed studies in knock-out mice lacking Mrp3 support the role of 
this basolateral efflux pump in the transport of bilirubin glucuronides from cells into blood (27). 
 
 The substrate specificity of MRP4 is relatively broad compared to other MRP subfamily 
members (21, 24, 28). This is due in part to the broadening of the substrate spectrum in the 
presence of GSH, which is normally present in living cells at millimolar concentrations, as 
exemplified by the MRP4-mediated ATP-dependent transport of bile acids (28) and leukotriene 
B4, which occur only in the presence of GSH. Additional substrates of MRP4 include 
leukotriene C4, prostanoids, cyclic nucleotides, ADP, urate, dehydroepiandrosterone 3-sulfate, 
and the synthetic nucleoside phosphonate analog 9-(2-phosphonylmethoxyethyl) adenine 
(PMEA) (24, 26).  
 
 Inhibitors of high selectivity are not yet available for MRP2, MRP3, or MRP4. Useful 
nonselective inhibitors, however, include several quinoline derivatives, developed as leukotriene 
D4 receptor antagonists such as MK-571. MK-571 was originally identified as a potent inhibitor 
of MRP1-mediated transport and is now widely used as a nonspecific in vitro inhibitor of the 
transport of many organic anions mediated by MRP1, MRP2, MRP3, and MRP4 (21). However, 
it should be noted that, in addition to the action of MK-571 on MRP subfamily members, this 
anionic quinoline derivative is a  potent inhibitor of the hepatocellular uptake transporters 
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OATP1B1, OATP1B3, and OATP2B1 (29).  Cyclosporin A acts as a good but nonselective 
inhibitor of MRP2, in addition to its more potent inhibition of MDR1, BSEP (30), and the uptake 
transporters OATP1B1 and OATP1B3 (29).  Corresponding inhibitory actions on uptake as well 
as efflux have been described for rifampicin and rifamycin SV. Thus, for studies in vivo and with 
intact cells, the lack of selectivity with respect to MRP subfamily members as well as the action 
of the inhibitors on uptake transporters must be considered. 
 
Genetic variants 
 A large number of genetic variants in the ABCC2 gene encoding MRP2 have been 
identified in various ethnic groups, but only some of these variants lead to loss of the MRP2 
protein or to loss of functionally active MRP2 in apical plasma membranes (23). A complete loss 
of functionally active MRP2 in the hepatocyte canalicular membrane has been recognized as the 
molecular basis of Dubin-Johnson syndrome (31), which is associated with mild, predominantly 
conjugated hyperbilirubinemia, and upregulation of  basolateral MRP3 in human hepatocytes and 
Mrp3 in Mrp2-deficient rats (21). Under this condition, MRP3/Mrp3 compensate for the 
impairment of MRP2/Mrp2 function by efflux into blood of conjugated bilirubin and other 
endogenous and xenobiotic anionic substrates of MRP2 and MRP3. 
 
 Multiple genetic polymorphisms exist in the ABCC3 gene (32). However, so far no major 
PK consequences have been documented. The ABCC4 gene is highly polymorphic, and large 
variability of ABCC4/MRP4 mRNA (38-fold) and protein (45-fold) expression was found in 
human liver, and significant upregulation was observed in livers of patients with cholestasis (33). 
A common single-nucleotide polymorphism (rs3765534; >18% in the Japanese population), 
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which reduces MRP4 function, seems to be associated with thiopurine-induced hematopoietic 
toxicity (34). 
 
Methodology for evaluating function 
 The exact substrate specificity of the ATP-dependent efflux pumps of the MRP subfamily, 
MRP2, MRP3, and MRP4, may be defined in inside-out-oriented membrane vesicles for which 
substrate concentrations can be adjusted and metabolism or complex formation, as it may occur 
in intact cells and in vivo, can be controlled. Moreover, Table 2 presents some recommended 
probe substrates and inhibitors.  It should be noted that many MRP substrates are only generated 
intracellularly in Phase II reactions forming the respective glutathione, sulfate, and glucuronide 
conjugates, as illustrated by S-(2,4-dinitrophenyl)glutathione and glucuronosyl bilirubin.  
 
 An extensive analysis of the prediction and identification of in vitro drug interactions 
with human MRP2 was published by Pedersen et al. (35) using inside-out-oriented membrane 
vesicles from Sf9 cells and estradiol-17β-D-glucuronide as the substrate. This study with a large 
set of structurally diverse drugs and drug-like compounds identified many inhibitors, 
noninhibitors, and even stimulators of MRP2-mediated transport (35). The stimulators exhibited 
similar charge distributions as MRP2 substrates, with at least one negative charge at physiologic 
pH. As pointed out above, such a study gains additional physiological relevance when performed 
in the presence and absence of GSH which is present in living cells at millimolar concentrations. 
Moreover, for drugs and drug candidates that undergo predominantly hepatobiliary elimination, 
it is essential to determine if glucuronate or glutathione conjugates are formed intracellularly and 
represent inhibitors or substrates of MRP2, MRP3, or MRP4. 
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 For a NME, it is important to examine MRP2 inhibition if drug-induced conjugated 
hyperbilirubinemia is observed in patients or in preclinical species. To date no classical PK DDI 
has been attributed to MRP2 and there is no evidence that MRP3 or MRP4 should be examined 
or that there is a likelihood of DDIs or toxicity due to being a substrate of MRP2. It is plausible, 
but not proven, that hepatotoxicity may result, however, from compounds or metabolites that 
potently inhibit MRP2 as well as MRP3 and MRP4 and thus cannot exit from hepatocytes via 
alternative pathways. 
 
 
The bile salt export pump (BSEP) and its role in hepatotoxicity 
General Description 
 In addition to elimination of drugs and xenobiotics, bile formation is another key function 
of the liver. Bile has two major physiologic functions: it provides a vehicle for excretion of 
poorly water soluble substances (e.g., cholesterol) and is essential for digestion and absorption of 
fat and fat soluble vitamins in the intestine. Bile is mainly composed of small ions, organic 
anions, lipids (e.g., phosphatidylcholine) and bile salts (36). Bile salts are amphipathic molecules, 
have detergent properties and are highly concentrated in bile (36) where they form mixed 
micelles with phospholipids, which act as carriers for poorly water soluble substances (36). Due 
to their detergent properties, bile salts can be highly toxic to hepatocytes if they accumulate 
intracellularly (37). 
 
 Bile salts are taken up from the sinusoidal blood plasma by several transporters into 
hepatocytes (38), where they mix with newly synthesized bile salts. Bile salts are secreted by the 
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BSEP into canaliculi, which constitute the starting points of the biliary tree (39, 40). The BSEP 
mediates the rate-limiting step of bile salt transport across hepatocytes for which there is not a 
backup system in the canalicular membrane. Consequently, any impairment of BSEP function 
can potentially lead to accumulation of cytotoxic bile salts in hepatocytes. 
 
Function 
 BSEP has a narrow substrate specificity and transports conjugated monovalent bile salts 
in addition to taurolitocholyl 3-sulfate (39, 41). Data on transport of unconjugated bile acids such 
as cholic acid are conflicting (40). For taurocholate, Km values ranging from 5 to 22 µM have 
been reported by different groups in different expression systems (40) and other bile salts have 
Km values in this range (40). The intrinsic clearances for human, rat and mouse BSEP have the 
same rank order (40, 42), indicating similar transport properties of BSEPs from these three 
species. In addition to bile salts, pravastatin has been reported to be a BSEP substrate, albeit with 
low affinity (40), and indirect evidence from sandwich-cultured hepatocytes suggests that the 
antifungal micafungin may be transported by BSEP (43). Taking together the evidence obtained 
so far, it seems unlikely that BSEP plays a major role in drug export from hepatocytes into bile 
and consequently in drug disposition. 
 
Genetic variants 
 Much has been learned about the physiologic role of BSEP from patients with inherited 
liver diseases due to impaired BSEP function. ABCB11 encoding BSEP was identified by 
positional cloning in families with progressive familial intrahepatic cholestasis (PFIC) type 2 
(44). Four mutations identified in this study predict premature truncation of BSEP, while the 
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other mutations are missense mutations. Such patients develop progressive cholestatic liver 
disease with low biliary bile salt concentrations (45). Basolateral efflux via MRP4 and the 
organic solute transporter OSTalpha/OSTbeta is not sufficient to compensate for genetic variants 
resulting in the absence of BSEP protein, clearly demonstrating the absence of a functional 
backup system in the canalicular membrane for secretion of bile salts. Some mutations in 
ABCB11 lead to less severe forms of cholestatic liver disease called benign recurrent intrahepatic 
cholestasis type 2 (BRIC2). The clinical spectrum of ABCB11 mutations covering BRIC2 to 
PFIC2 is also known as BSEP deficiency syndrome (45). 
 
 It can be inferred from patients with benign BSEP deficiency syndrome that in symptom-
free intervals the residual BSEP transport capacity is sufficient for a seemingly normal liver 
function. Consequently, inhibition of BSEP activity by endogenous or exogenous substances 
below (a yet unknown) threshold function can lead to cholestasis. Cyclosporine is a drug leading 
to acquired cholestasis and consequently to drug induced liver injury (DILI) in some patients 
(41). Using rat Bsep as a model, competitive inhibition of Bsep by drugs known to be associated 
with drug-induced cholestasis was demonstrated (46). This finding was later extended to human 
BSEP (42, 47). To date, a large variety of drugs and xenobiotics have been reported to interfere 
with BSEP function in vitro, the information for which is summarized in (40, 41, 48, 49). 
 
 Drug-induced cholestasis is a rare but often serious side effect of drugs (50). 
Consequently, investigations for identification of susceptibility factors are ongoing, but have so 
far proved difficult (50). With respect to factors affecting BSEP, information is scarce. The most 
common polymorphism in ABCB11 is c.1331T>C (p.V444A) and is ethnicity dependent with a 
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frequency around 60% in Caucasian populations (51). The c.1331C variant leads to lower BSEP 
protein levels (52) and is overrepresented in patients with drug induced cholestasis as well as in 
patients with intrahepatic cholestasis of pregnancy (50, 51). As the two BSEP variants have 
indistinguishable kinetic properties and both variants are almost equally abundant in some 
populations, the role of this polymorphism as a susceptibility factor for drug- induced cholestasis 
is, as yet, unknown.  
 
Methodology for evaluating function 
 Bile salts are negatively charged and can barely cross membranes. Therefore, studies with 
isolated membrane vesicles are the best technical approach to investigate transport mediated by 
BSEP. ATP-dependent taurocholate transport into canalicular plasma membrane vesicles is 
electrogenic (40). Inhibition studies with NMEs and BSEP are preferentially done at taurocholate 
concentrations of 5 to 10 µM in the presence of a permeant anion (for compensation of charge 
movement). The suggested taurocholate concentration is in the range of the Km value of BSEP 
(40) and allows an estimation of Ki values from IC50 values. If a NME inhibits BSEP with a low 
Ki value, additional experiments may be warranted. One additional test system for a NME is 
human hepatocytes cultured in a sandwich configuration (53). This system offers the advantage 
that it is metabolically competent and to some extent includes the potential impact of metabolites 
on BSEP. In addition, experiments in a preclinical species, e.g. rats, may be warranted. If the 
NME is also an inhibitor of rat Bsep, application of the NME in a repeat dose study for several 
weeks to animals at a dose leading to at least the expected human serum concentrations will be 
helpful. It is recommended that this test includes sampling of serum on a daily basis followed by 
measurements of bile salt concentration, alkaline phosphatase, and transaminases. A course of 
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serum parameters showing a steady increase of bile salts, even if before elevation of 
transaminases, points to a likely Bsep interaction. At the end of the experiment, bile flow may be 
determined in control and treated animals, as any reduction of bile flow is a very sensitive 
indicator for cholestasis. If a NME showing a Bsep interaction in rodents is given to humans, 
serum bile salt levels as well as serum markers may be monitored from the very beginning. For 
humans, the revised standards for drug-induced liver injury may serve as a guideline (54). 
 
Clinical significance and drug development recommendations 
 The decision whether or not to investigate a NME for BSEP interaction may depend on 
various factors. As BSEP is an unlikely player in disposition of NMEs, concerns may focus on 
potential DILI related to BSEP. Here, inhibition of BSEP will lead to intracellular accumulation 
of bile salts followed by cytotoxic events. 
 
 Currently, it is impossible to define a value for a BSEP inhibition constant that will 
realistically predict significant BSEP-mediated DILI. The reasons are: 1) While a trend between 
low IC50 values of BSEP inhibition and DILI was described (48, 49), no correlation between 
Cmax, unbound with the potency of BSEP inhibition and with DILI was observed (48), showing that 
the uptake mechanism of drugs into hepatocytes is a major contributor to intracellular drug 
concentrations. At present, the exact transport mechanism and in particular the energetics of the 
OATPs, which are the major drug uptake systems into hepatocytes, are poorly understood. It 
should also be noted that cyclosporin A is a very potent BSEP inhibitor although it is widely 
used in solid organ transplantation despite the occurrence of cholestatic episodes. In addition, 
there is large interindividual variability of BSEP protein levels in normal human liver 
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contributing to adverse actions (52). 2) Many drugs form an array of metabolites, some of which 
may be even more potent BSEP inhibitors than the parent drug and act synergistically. Examples 
are troglitazone and bosentan (41).  The bosentan interaction is discussed in its EU label. 3) 
Some drugs may in addition to interference with BSEP also impair mitochondrial function (e.g., 
troglitazone (41)) forming reactive intermediates. Such a situation may lead to a synergism in 
toxicity, as elevated intracellular bile salts may aggravate mitochondrial toxicity of a metabolite 
(41). And 4) There are BSEP inhibitors that require parallel transport activity of BSEP and 
MRP2 in the same membrane. This was first demonstrated for estradiol 17β-glucuronide (46) 
and later for drug metabolites (50). Drugs have been identified that are BSEP inhibitors but are 
not associated with DILI. In conclusion, prospective BSEP testing cannot be endorsed at this 
moment without a strategy to assess clinical relevance of such inhibition, but in vitro 
characterization of BSEP-drug interactions are certainly warranted after the appearance of 
cholestatic issues in clinical trials or safety studies.  However, the EMA DDI guideline states that 
investigating BSEP inhibitory potential should be considered. If inhibition is indicated, adequate 
biochemical monitoring including serum bile salts is recommended during drug development. 
 
 
Other Transporters of Clinical Importance 
 
The transporters described above and in the previous ITC white paper have the potential 
to interact with a broad range of drugs.  However, it is important to keep in mind that for certain 
classes of drugs other transport mechanisms may be important.  Two such examples are given 
below:  Human equilibrative nucleoside transporter 1 (hENT1) which is important in the delivery 
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of certain drugs to tumors and the human intestinal Peptide Transporter which is important in the 
oral delivery of many peptide-like drugs. 
 
Human equilibrative nucleoside transporter 1 (hENT1) 
General description 
 Nucleosides have diverse roles in many processes, including cellular metabolism, 
signaling and proliferation.  Many nucleoside analogs are used clinically for treatment of cancer 
and viral diseases.  Since most nucleosides are hydrophilic, their cellular uptake and release is 
dependent on the activity of membrane transport proteins.   Two evolutionarily unrelated protein 
families are responsible for nucleoside transport in humans: the Solute Carrier (SLC)28 and 
SLC29 families of nucleoside transporters (NTs), whose members are known, respectively, as 
the human (h) concentrative and equilibrative NTs (hCNTs; hENTs)(for recent reviews see (55-
57)).  Three isoforms in the hCNT family and four in the hENT family have been identified and 
functionally characterized by molecular cloning and expression of their cDNAs.   These isoforms, 
the genes encoding them and their chromosomal locations are:  hCNT1, SLC28A1, 15q25.3; 
hCNT2, SLC28A2,  15q15; hCNT3, SLC28A3, 9q22.2; hENT1, SLC29A1, 6p21,1; hENT2, 
SLC29A2, 11q13; hENT3, SLC29A3, 10q22.1; hENT4, SLC29A4, 7p22.1.  The focus in this 
whitepaper will be on hENT family members and their roles in delivery of drugs to tumors. 
Current understanding of the distribution of hENTs in intestine, kidney, liver and brain (57) is 
summarized in Figure 1 . 
 
Among members of the hENT family, the properties of hENT1 and hENT2 are well 
established (56).  Both translocate nucleosides bidirectionally down their concentration gradients, 
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have broad substrate selectivities, and are widely distributed among tissues. They are 
functionally distinguished by differences in their sensitivities to transport inhibitors.  hENT1 is 
potently inhibited by nitrobenzylmercaptopurine ribonucleoside (NBMPR) and its structural 
analogs with Ki values in the nM range whereas hENT2 is relatively insensitive with Ki values in 
the µM range.  Because NBMPR and its structural analogs are highly specific for hENT1, they 
have been used extensively as molecular probes for identification and isolation of hENT1 in cells 
and tissues.  hENT1 and hENT2 are integral membrane proteins with 11 transmembrane helices 
and regions important for inhibitor and substrate interactions have been identified for both 
proteins (57).   
 
hENT1 and hENT2 both transport a wide range of purine and pyrimidine nucleosides, and 
hENT1 has higher apparent affinities for its substrates than hENT2.   Both also have the capacity 
to transport nucleobases (hENT2 > hENT1), although the physiological importance of these 
activities is unknown (56, 57).  In general, nucleoside analog drugs are poorer substrates for 
hENT1 and hENT2 than their physiological counterparts. Among clinical anticancer nucleosides, 
fludarabine, cladribine, clofarabine, 5-fluorouridine, 2'-deoxy-5-fluorouridine, azacytidine and 
decitabine are substrates of both, whereas gemcitabine and cytarabine are preferred by hENT1.  
Among clinical antiviral nucleosides, hENT2 appears to be more important than hENT1 in 
cellular uptake of zidovudine, zalcitabine and didanosine.   
 
Transport assays   
Because most human cell types contain multiple hNT types, the most reliable functional 
studies of hNTs are those conducted with (i) recombinant proteins produced individually in 
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otherwise NT-deficient cells, primarily the yeast Saccharomyces cerevisiae (engineered to lack 
NT activity), oocytes of Xenopus laevis (lack endogenous NT activity) and human cell lines 
(mutants that lack NT activity) and (ii) native proteins in cells that either produce a single 
transporter type (e.g., hENT1-containing human erythrocytes) or that can be manipulated 
pharmacologically by treatment with selective NT inhibitors such that only a single transporter 
type is functional (e.g., treatment of hENT1/2-containing cells with NBMPR).  For 
methodological details see (58, 59).  Studies of radioisotope fluxes can be undertaken with these 
systems to identify substrates and inhibitors, which for some hNT and cell combinations is 
difficult because of rapid equilibration of intra and extracellular nucleosides.      
  
Clinical implications: hENT1 in anticancer therapies with nucleoside drugs  
 Although the potential role of hENT1 in the clinical activity of nucleoside drugs has been 
recognized for decades (reviewed in (60)), evidence of its importance has only recently been 
obtained. The development of monoclonal antibodies against hENT1 (61) provided the tools for 
analysis of the distribution of hENT1 in human tissues, including immunohistochemistry studies 
of human cancer samples, which revealed marked variations in its abundance in a variety of 
cancers, giving rise to the hypothesis that low levels of hENT1 in target tumors predicts 
resistance to nucleoside drugs. In a retrospective study of pancreatic adenocarcinoma samples 
from deceased patients who received gemcitabine mono-chemotherapy for palliation, patients 
whose tumor cells all exhibited hENT1 immunostaining had longer survival times than those 
whose tumors contained cells that lacked hENT1 immunostaining (13 vs 4 months), indicating a 
relationship between hENT1 abundance and response to gemcitabine (62). A subsequent study of 
hENT1 abundance and gemcitabine therapy in a larger group of pancreatic adenocarcinoma 
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patients yielded similar findings (63). It has been proposed that resistance to nucleoside drugs 
because of low hNT abundance in target tumor cells can be circumvented by the development of 
nucleoside drugs that enter cells by other routes (e.g., passive diffusion).   Since pharmacologic 
resistance to anticancer nucleoside drugs is likely if other drugs administered simultaneously 
inhibit cellular uptake, NMEs with nucleoside-like structures may be assessed for their potential 
to inhibit hENT1 if they are likely to be administered with ENT substrates. 
 
 
Peptide transport  
 
 Another class of transporter that will handle selected targeted drugs is the Peptide 
Transporter Family (gene symbol SLC15) (64).  There are four transporters in the SLC15 family 
(SLC15A1-4). The proteins encoded and their chromosomal location are PEPT1 (SLC15A1, 
13q33-q34 ), PEPT2 (SLC15A2, 3q13.3-q21), PHT1 (SLC15A4, 12q24.32) and PHT2 (SLC15A3, 
11q12.2).  PHT1 and 2 transport histidine and peptides and have not been shown clinically to 
play a major role in the disposition of drugs.  PEPT1 and PEPT2 are the most studied 
transporters in the family and are key in the disposition of peptide-like drugs (e.g., beta lactam 
antibiotics, ACE and renin inhibitors) and in peptide prodrugs (valacyclovir)(65).  PEPT1 is 
apically located in the intestine and to a lesser extent in the kidney.  PEPT1 is responsible for the 
uptake of di- and tri- peptides from the intestinal lumen into the blood and in the kidney for the 
scavenging of peptides from the urine back into the renal proximal tubule cells.  PEPT2 is 
located in the kidney, but is also found at the blood cerebrospinal fluid barrier and the lung.  
PEPT2 is the primary mechanism in the proximal tubule cells for the reabsorption of di- and tri-
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peptides from the urine.  In the brain, PEPT2 is used to clear di- and tri-peptides from the 
cerebrospinal fluid (CSF) back into the blood and in the lung PEPT2 absorbs peptides.   
 
 Because of PEPT1’s location and absorptive function in the intestine, it is a useful 
mechanism to increase the bioavailability of small, hydrophilic, charged molecules (64).  It has 
been utilized to increase the bioavailability of amino acid- and nucleoside-like drugs.  It is also 
known to transport some antibiotics.  It transports molecules via a proton dependent mechanism 
taking advantage of the acidic micro-environment of the intestine to co-transport a substrate 
along with a proton(65).  PEPT1 is considered a low affinity high capacity transporter.  The 
affinity (Km) for natural substrates is in the high micromolar range and for drugs such as beta 
lactam antibiotics the Km values are in the low millimolar range.  However, since it has high 
capacity and is expressed along the length of the gut, it efficiently scavenges its substrates’ 
uptake into intestinal enterococytes where they are eventually shunted into the blood. 
 
 The genetics of PEPT1 have been studied in vitro and the most frequent coding region 
SNP (S117N) does not lead to functional change in vitro (66).  Two SNPs that do lead to 
functional changes in vitro (P586L and F28Y) have very low frequency in all populations studied 
to date (65).  To date no clinical consequences for any PEPT1 variants have been found.   
 
 Functional studies for PEPT1 have been carried out in a number of heterologous 
expression systems.  The transporter is easily expressed transiently in mammalian cell lines such 
as HEK, COS or HeLa or it can also be stably expressed (64).  Many laboratories have also used 
oocyte expression to study peptide transport.  PEPT1 is also expressed in intestinal cell lines 
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such as CACO-2.  However, the expression level is low and requires 14 to 21 days in culture for 
maximal expression.  The role of PEPT1 in absorption can also be studied in knockout mice (67). 
Although the knock-out strains have been characterized and used to study probe substrates, they 
are not currently commercially available. 
 
Clinical significance and drug development recommendations 
 PEPT1 works well as a mechanism for oral delivery of small charged amino acid, peptide 
or nucleoside like drugs (65).  The transporter appears not to be easily saturated and can deliver 
relatively large doses of drugs.  For example, the cephalosporin antibiotics are given at gram 
doses.  Review of labels for drugs (e.g., cephalosporins, valacyclovir, enalapril) that utilize 
peptide transporters for absorption shows little concern for interactions during absorption as 
there are no consistent food interactions or interactions with other drugs transported by PEPT1.  
It is of note that PEPT1 appears to be upregulated in inflammatory bowel disease leading to 
expression of  PEPT1 in the colon which is believed to be part of the proinflammatory response 
(68).  Thus, although PEPT1 is normally thought of as a delivery mechanism, it may also be a 
pharmacological target for inflammatory bowel disease.  There have also been studies as to its 
role in various cancers as a possible delivery mechanism (64, 65).  
 
 
SUMMARY AND FUTURE PERSPECTIVES  
 
 
 Membrane transporters of emerging importance in pharmacokinetics, drug-drug 
interactions, and interference of drugs with the transport of endogenous compounds are 
discussed in this paper. We focus here on human transporters involved in the uptake and efflux 
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of drugs that were not considered in detail in our previous ITC whitepaper on membrane 
transporters (2).  
 
 The multidrug and toxin extrusion proteins (MATEs) were discovered only in 2005 (11) 
and include MATE1, MATE2 and the splice variant MATE2K. They are expressed abundantly 
in the apical membrane of the renal proximal tubule and play a role in the secretion of cations 
and zwitterions into the urine. MATE1 is also highly expressed in the canalicular membrane of 
hepatocytes where it contributes to biliary excretion of cationic compounds.  Many clinically 
used drugs, including metformin, cimetidine, and acyclovir, were identified as substrates for 
MATEs. There is compelling in vitro and in vivo evidence that MATEs are major sites of renal 
drug-drug interactions.  ITC recommends that NMEs be evaluated as potential substrates or 
inhibitors for MATEs along with OCT2 and OAT1/OAT3, and decision trees for evaluating the 
interactions of MATEs with NMEs are presented.  These decision trees will need to be tested in 
the clinic and revised if necessary as more data becomes available. 
 
 Within the subfamily of multidrug resistance proteins (MRPs, ABCCs), the ATP-driven 
efflux pumps MRP2, MRP3, and MRP4 have received particular attention because of their role 
in the disposition of anionic drugs and anionic conjugates. Human MRP2 is localized to the 
apical membrane of hepatocytes, intestinal epithelia, and proximal tubules of the kidney. 
Accordingly, it is essential for the hepatobiliary and renal elimination of many anionic substrates, 
including drugs and conjugates such as bilirubin glucuronides. In hepatocytes, MRP3 and MRP4 
are localized to the basolateral (sinusoidal) membrane and mediate efflux of substrates, 
particularly glucuronides and glutathione conjugates, into sinusoidal blood and play a 
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compensatory role in cholestasis. Human MRP4 has a number of localizations important for drug 
elimination and action, including its presence in the apical (luminal) membrane of the kidney 
proximal tubule, the epithelium of the blood-brain barrier and membranes of the blood platelet. 
Drug-induced conjugated hyperbilirubinemia, in patients or in preclinical species, points to an 
inhibition of MRP2. Thus, under many conditions, conjugated hyperbilirubinemia may 
necessitate in vitro analyses using, for instance, inside-out-oriented membrane vesicles to 
elucidate the interaction of a compound with MRP2.  
 
 The bile salt export pump (BSEP) is exclusively localized in the hepatocyte canalicular 
membrane and prevents accumulation of toxic concentrations of bile salts in hepatocytes by 
unidirectional ATP-dependent transport into the biliary tree. BSEP has no functional backup and 
impairment of BSEP function may lead to liver disease as evidenced by increased plasma bile 
salt concentrations and liver enzymes. NMEs leading to cholestasis with increased plasma bile 
salt concentrations in preclinical species or in humans may be examined for their inhibitory 
potential using inside-out membrane vesicles containing recombinant human BSEP in ATP-
dependent transport assays with taurocholate (cholyltaurine) as a probe substrate.  Future work is 
needed to identify susceptibility factors and/or genes leading to drug-induced cholestasis due to 
BSEP impariment. Such information may be obtained from retrospective analysis of clinical data, 
but will subsequently need to be verified in prospective multicenter trials.  
 
 
 Other transporters have shown importance in drug delivery. In this whitepaper, we 
presented two examples, NTs and PEPTs.   
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 NTs (e.g., hENT1) are important for the uptake of nucleosides and their analogs into cells 
and are widely distributed among cells and tissues in humans. Many nucleoside analogs are used 
clinically for treatment of cancer and viral diseases. Recent data showed a correlation between 
abundance of hENT1 and survival of pancreatic cancer patients treated with gemcitabine. 
 
 Peptide transporters, as exemplified by PEPT1 in the apical membrane of small intestine, 
are not only important for nutritional absorption of di- and tri-peptides but also for delivery of 
amino acid-like or dipeptide-like drugs and prodrugs. Drug substrates include many ß-lactam 
antibiotics and prodrugs such as valaciclovir. Transporter assays (e.g., using transfected PEPT1-
expressing HeLa cells) serve not only in studies on the substrate properties of new chemical 
entities but also in the in vitro analysis of drug-drug interactions. 
 
 Consistent methods for studying transporters are still under development.  However, 
recommendations and a detailed discussion of determination of kinetic parameters of transporter 
substrates are given in an accompanying article in this issue (69).  In brief, transport studies with 
transfected cells are recommended for uptake transport systems while transport studies with 
inside-out vesicles isolated from transfected cells are recommended for efflux transporters. 
Kinetic parameters have to be determined using conditions of initial uptake rates. For inhibition 
experiments Ki values obtained from Dixon plots are preferred over IC50 values.  
 
 In summary, NMEs that are actively renally secreted are recommended for investigation 
as a MATE1 or MATE2K substrates in addition to being investigated as OAT1, OAT3 or OCT2 
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substrates according to Figure 2.  It is recommended that the potential of all NMEs to inhibit 
MATE1 and MATE2k be determined in vitro. Figure 3 may be followed to determine if a 
clinical interaction study is necessary.  The inhibition of both BSEP and MRPs has the potential 
to cause cholestasis and if  signs of cholestasis are seen, retrospective analysis of inhibition of 
the BSEP and MRPs can help determine the mechanism of toxicity.  Because there are no known 
cut-offs for the inhibition potential (IC50 or Ki values) of these transporters that indicate 
increased risk of hepatotoxicity, screening of their inhibition on a routine basis is not yet 
warrented.  Three other transporters that were highlighted in this review, hENT1, hENT2 and 
PEPT1, although examples of transporters that do not need to be routinely screened, are also 
known to distribute specific type of drugs and thus are important determinants for efficacy and 
distribution.  The hENTs transport nucleoside drugs and PEPT1 transports a variety of drugs 
with peptide-like properties.  
 
Disclaimer: 
 
The opinions expressed in this paper reflect the views of the authors and should not be construed 
to represent FDA’s views or policies. 
 
Lei Zhang has no conflict of interest to report. 
 
Carol Cass is a paid consultant for Clavis Pharma. The University of Alberta licensed antibodies 
against hENT1 produced in Cass's research laboratory to Clavis Pharma (Oslo, Norway) for use 
in diagnostic assays to predict response of cancer patients to nucleoside derivatives produced by 
Clavis that enter cells independently of nucleoside transport systems. 
 
 
 
Ac
ce
pte
d m
an
us
cri
pt
ACCEPTED ARTICLE PREVIEW 
© 2013 American Society for Clinical Pharmacology and Therapeutics. All rights reserved 
Figure Legends 
 
 
Figure-1: Proposed expansion of transporters for evaluation during drug development by 
ITC. 
Proposed expansion of transporters for evaluation during drug development by ITC.  
Transporters were highlighted on the basis of evidence of clinical drug interactions and relevance 
to toxicity or efficacy, as well as availability of in vitro assays, substrates and inhibitors. 
Transporters recommended for evaluation in the 2012 FDA Draft Drug Interaction Guidance are 
marked with red circles.  MATEs (green circles) are being proposed for prospective investigation 
in drug development as discussed at the ITC Second Workshop.  In addition MRP2 and BSEP 
inhibition are recommended for retrospective studies based on preclinical and clinical 
observations (yellow circles.)  Examples given in this paper (ENTs and PEPTs) are in light blue 
circles.  Modified from ref. 8 by Sook Wah Yee, University of California, San Francisco. 
 
 
Figure 2: Decision tree for renally cleared substrates proposed by ITC  
a.  For simplicity organic anion transporters, OAT1 and OAT3 are not included; however, if 
secretory clearance is an important route of elimination, NMEs should also be studied as 
substrates of OAT1 and OAT3.   
a-Percent (%) active renal secretion was estimated from (CLr–fu*GFR)/CLTotal; fu is the 
unbound fraction in plasma (6).  
b-The ratio of the investigational drug uptake in the cells expressing the transporter versus the 
control (or empty vector) cells should be greater than 2. It is important that uptake into the 
transfected cells be significantly greater than background in a control cell line and be inhibited 
by a known inhibitor of the transporter. Michaelis–Menten studies may be conducted in the 
transfected cells to determine the kinetic parameters of the investigational drug. A positive 
control should be included. In an acceptable cell system, the positive control should show a ≥ 2 
fold increase in uptake compared to vector-transfected cells. An uptake ratio (transporter 
transfected vs. empty vector transfected cells) other than 2 may be used if a ratio of 2 is deemed 
non-discriminative as supported by prior experience with the cell system used.  
c-If the NME interacts with OCT2 and MATE1/2K, suggested inhibitors to use for a clinical 
DDI study are pyrimethamine or cimetidine, both of which are clinically validated.  If the NME 
is a substrate of  OAT1 or OAT3 and MATE1/2K, probenecid should be considered for use as an 
inhibitor.   
 
 
Figure-3: Decision tree for renal transporter inhibitors proposed by ITC  
a-First step might be uptake of model substrate decreases with increasing concentration of NME, 
then full IC50 curve (modified from Ref 6).  
b-For NME that is a MATE1, MATE2K or OCT2 inhibitor, metformin may be used as the 
substrate for the clinical drug interaction study.  
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Table 1: Selected putative MATE-mediated clinical drug-drug interactions 
Interacting drug Affected drug Clinical effect on affected drug Ref. 
Fexofenadine 39% decrease in CLr of fexofenadine (70) 
Metformin 50% decrease in CLr of metformin 
and 27% increase in AUC 
(71) 
Dofetilide 33% decrease in CLr of dofetilide, 
48% and 29% increase in AUC and 
Cmax respectively 
(72) 
Chepalexin 33% decrease in CLr of cephexin (73) 
Cimetidine (400-
800mg, PO) 
Procainamide 44% decrease in CLr of 
procainamide and 35% increase in 
AUC 
(74) 
Chepalexin 
(500mg, PO) 
Metformin 14% decrease in CLr of metformin, 
24% and 34% increase in AUC and 
Cmax respectively 
(75) 
Metformin 35% decrease in CLr of metformin, 
42% and 39% increase in Cmax and 
AUC respectively 
(20) Pyrimethamine 
(50mg, PO) 
Creatinine 20% decrease in CLr of creatinine (20) 
Legend:  
Percent change refers to the difference in the presence or absence of interacting drug 
normalized to the value in the absence of interacting drug. 
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Table 2.  Recommended In Vitro Probe Substrates and Inhibitors for Human MRPs and 
BSEP ((69) and references therein). 
 
Transporter Substrates Inhibitors 
ABCC2 (MRP2) [3H]-leukotriene C4 
3H]-estradiol 17ß-glucuronide 
carboxy-dichlorofluorescein  
MK-571  
benzbromarone  
ABCC3 (MRP3) [3H]-estradiol 17ß-glucuronide,  
[3H]-methotrexate  
carboxy-dichlorofluorescein  
Bromosulfophthalein  
MK-571  
ABCC4 (MRP4) [3H]-leukotriene C4  
[3H]-dehydroepiandrosterone 
3-sulfate (DHEAS)  
[3H]-folate 
 
MK-571 
 
 
ABCB11 (BSEP) [3H]-taurocholate (cholyltaurine)  cyclosporin A 
PSC-833 
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